Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Hematological NeoplasmsHematopoietic Stem Cell Transplantation
Interventions
DRUG

Busulfex, Fludarabine, ALemtuzumab

Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1

Trial Locations (1)

73104

University of Oklahoma Health Sciences Center, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER

NCT00582894 - Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases | Biotech Hunter | Biotech Hunter